Personalized mRNA Vaccine Marks First Success in Melanoma Phase 3 Trial, Signaling a Paradigm Shift in Cancer Treatment
Background
The field of cancer treatment has long sought methods to selectively eliminate cancer cells while protecting healthy ones. The introduction of immune checkpoint inhibitors, which activate the immune system to treat cancer, significantly improved response rates. However, limitations remain, including variable patient responses and high recurrence rates, due to the unique mutation patterns of cancer cells that differ between individuals. Conventional precision medicine has primarily focused on prescribing gene-targeted therapies for common mutations, such as the BRAF mutation found in about half of melanoma patients. Most patients, however, have not received treatments tailored to their unique cancer cell profiles. To address this unmet need, a new preventive vaccine technology that analyzes individual tumor maps and directly trains immune cells is required.
Key Findings
The results of a Phase 3 clinical trial of V940, a personalized messenger ribonucleic acid (mRNA) cancer vaccine candidate jointly developed by pharmaceutical companies Merck and Moderna, have been officially published. Named INTerpath-001, this large-scale study involved 1,137 patients with surgically resected stage IIB to IV cutaneous melanoma. Participants were randomly assigned to either a group receiving V940 in combination with the immune checkpoint inhibitor pembrolizumab or a group receiving pembrolizumab alone for comparative observation.
Clinical trial analysis revealed that the group receiving the vaccine in combination with the immune checkpoint inhibitor showed statistically significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared to the group receiving the immune checkpoint inhibitor alone. These results confirm the positive trends observed in the earlier Phase 2b trial (KEYNOTE-942), which demonstrated nearly halving the recurrence risk in melanoma patients.
This treatment differs fundamentally from conventional vaccines in its mechanism of action. After medical professionals extract and decode the patient's tumor tissue, Moderna's artificial intelligence (AI) algorithm predicts the neoantigens most likely to induce an immune response. Based on this information, a personalized mRNA vaccine is individually designed and manufactured, then administered to the patient. This enables immune cells to precisely target and attack residual cancer cells within the patient's body.
Significance and Outlook
The success of V940 in Phase 3 trials marks a significant milestone in building trust in personalized therapies not only for cancer treatment but also for rare genetic diseases. The pharmaceutical and biotechnology industry is witnessing a shift from mass production of standardized drugs to a customized production system capable of manufacturing vaccines tailored to individual patients. However, practical challenges remain before commercialization. On average, it takes several months to analyze a patient's tumor tissue, precisely design a personalized vaccine, and complete the final production. For patients with rapidly progressing advanced-stage cancer, the disease may worsen before the vaccine is ready. Long-term survival rate tracking over the next several years will be necessary to verify whether the treatment group experiences actual life extension.
Nature, Published online: 21 August 2026; doi:10.1038/d41586-026-02638-7Good news from a trial of a vaccine against melanoma. Plus, the US NSF is set to issue its lowest number of new grants in forty years, and the living layer that protects and produces desert soils.
In clinical practice, a preventive scenario that enables early delivery of personalized immunotherapy to high-risk patients with a high recurrence risk after surgery is now feasible. Patients can request tumor tissue analysis immediately after tumor resection surgery and wait for approximately 4 to 6 weeks while receiving standard immune checkpoint inhibitor therapy. During this time, the AI-designed V940 vaccine is completed and delivered, after which the patient receives the combination of the standard therapy and the personalized vaccine to eliminate residual cancer cells and reduce recurrence rates. Industrially, advanced gene sequencing technology and individualized production facilities are required, and a new collaborative network between pharmaceutical companies and precision medicine infrastructure is expected to be established.